The Longevity Market Lacks Accessible Products

The longevity market is enormous. But I still can’t figure out what a normal person is supposed to buy. Not someone like me who works in this industry. Someone who doesn’t know a longevity doctor. Who doesn’t read PubMed. Who doesn’t know which biomarkers matter, which supplements are mostly marketing, or whether they should be taking peptides, metformin or nothing at all. What do we actually offer that person today? Supplements with increasingly sophisticated marketing. Peptides being commercialized faster than the evidence is developing. Thousands of dollars of tests, followed by a PDF. And at the other end, $20k, $50k, $100k+ concierge longevity programs accessible to a tiny percentage of the population. There is strangely little in the middle. And that’s what I find interesting. Because I don’t think the biggest gap in longevity right now is science. We already have a lot to work with: decades-old drugs with known safety profiles, increasingly sophisticated diagnostics, continuous data from wearables, imaging, genetics and much better understanding of prevention. The gap is turning all of that into a product. Something a normal person can actually walk in and get. Evidence-based. Personalized. Actionable. And affordable enough to scale. We’ve built a lot of longevity infrastructure. I’m not convinced we’ve built the longevity product yet. And I keep wondering who will. Will it come from medicine? Or will it come from people who understand how to build consumer products? Because they may start with the same science and build completely different things.